Essential Thrombocythemia, ET
12
3
5
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
17%
2 trials in Phase 3/4
57%
4 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (12)
National Longitudinal Cohort of Hematological Diseases
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms
Agrylin Drug Use-Result Survey
Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®
Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia
Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia
Pediatric Disease Registry in Essential Thrombocythaemia (ET)